Research program to elucidate the molecular biological mechanism of action of NMN started with the Systems Biology Research Organization, a non-profit organization.

Shinko Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo; CEO: Megumi Tanaka) has launched a series of life science research programs focusing on the mechanism of action and effects of Nicotinamide Mononucleotide (NMN).

For the press release, please see here.